Quantel Medical today announced the CE mark approval of LacryStimTM IPL system. Based on intense pulsed light technology, LacryStimTM is used for the treatment of dry eye diseases such as Meibomian gland dysfunction.
Dry eye disease is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment. It affects all populations across the world with a major increase in people over 50 years old and is expected to increase as the population continues to age.
LacryStimTM IPL is a treatment device featuring a unique wavelengths spectrum and train of pulses enabling the stimulation of the lachrymal and Meibomian glands and the reduction of inflammation. These mechanisms of action help the improvement of the tear film quality and the reduction the major symptoms associated with mild to moderate dry eye diseases. “LacryStimTM IPL system is the second product of our dry eye range and brings an innovative therapeutic solution to ophthalmologists confronted to the daily challenge of dry eye treatment. It complements ideally with LacryDiagTM , our dry eye diagnostic platform launched in 2018.” said Jean-Marc Gendre, CEO of Quantel Medical. “With the release in 2017 of the DEWS 2 report setting new standards of diagnosis and treatment, Quantel Medical is proud to bring a complete diagnosis and treatment solution that meets with the requirements of the new standards of care in dry eye diseases.”